Market Research Report

A quick peek into the report

Europe Nucleic Acid Therapeutics CDMO Market

Analysis and Forecast, 2023-2033

 
Some Faq's

Frequently Asked Questions

Pharmaceutical companies involved in the manufacturing, and commercializing of drugs, should buy this report.

The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033

CDMO stands for Contract Development and Manufacturing Organization. In biotech, CDMOs provide services to pharmaceutical and biotechnology companies, offering expertise in drug development, manufacturing, and related processes on a contractual basis. They assist in bringing new therapies to market efficiently by leveraging their specialized capabilities and infrastructure.

 

Nucleic acid-based therapeutics are medications that utilize nucleic acids, such as DNA or RNA, to treat diseases. They work by targeting specific genes or gene products involved in disease processes, aiming to modify gene expression, regulate protein production, or correct genetic abnormalities, offering promising treatments for various medical conditions.

Antisense oligonucleotides: Inhibit gene expression by binding to target mRNA.

siRNA (small interfering RNA): Silence specific genes by triggering mRNA degradation.

mRNA (messenger RNA): Deliver genetic instructions for protein synthesis.

Gene editing tools (e.g., CRISPR/Cas9): Modify genomic DNA to correct or alter genetic sequences.

Similar Product

You may also like

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis
Published Year: 2023

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis

The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is...